Your session is about to expire
← Back to Search
New Cancer Treatment for Non-Hodgkin's Lymphoma
Study Summary
This trial is testing a new cancer treatment for children with B-cell NHL. The new treatment is based on the successful LMB-96 regimen. The trial features prospective biologic and late effect studies.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with a specific type of lymphoma (like Burkitt or large B-cell).I have not received any treatment for my condition, except possibly a short course of steroids, one spinal chemotherapy session, or emergency radiation.I was diagnosed before turning 22 years old.I need a hepatitis test before starting treatment because my cancer is high-risk.I have been screened for Hepatitis B before starting rituximab treatment.My lymphoma is not classified as a mature B-cell type.
- Group 1: Group B
- Group 2: Group C
- Group 3: Group A
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants will this research project be testing?
"Unfortunately, this study is no longer looking for patients. It was last updated on September 23rd, 2010. However, there are 2906 trials for lymphoma and 1904 trials for this treatment with open recruitment."
What are the main aims of this research project?
"The principle aim of this study, which will follow patients for approximately 1 year after they have completed treatment, is to gene profile Burkitt Lymphoma (BL) versus non-BL. Additionally, researchers will secondary outcomes including Event-free survival and number of possible rituximab-related toxicities. Event-free survival is defined as the estimated percentage of patients treated at SJCRH who do not experience a pre-defined set of negative events, including death while in continuous CR, relapse, secondary malignancy, or failure to achieve complete response (CR). The number of episodes and the cumulative incidence throughout the treatment period"
Can you give me some more information about this treatment's success in other studies?
"There are a total of 1904 active clinical trials researching this treatment, with 422 of them being in Phase 3. Out of the 68566 clinical trial locations, some are based in Bethesda, Maryland."
What are the usual conditions that doctors use this therapy to improve?
"This new treatment shows potential in the treatment of lung cancers, thyroiditis, and polyangium."
Can patients sign up for this trial at this time?
"According to the information available on clinicaltrials.gov, this clinical trial is not enrolling patients at this time. The trial was originally posted on 2010-09-09 and was last edited on 2022-09-23. However, there are 4810 other clinical trials that are enrolling patients right now."
Share this study with friends
Copy Link
Messenger